Insigneo Advisory Services’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.23M Buy
9,736
+676
+7% +$89.1K 0.05% 275
2026
Q1
$1.26M Buy
9,060
+2,037
+29% +$285K 0.09% 193
2025
Q4
$862K Sell
7,023
-178
-2% -$21.6K 0.06% 241
2025
Q3
$799K Sell
7,201
-104
-1% -$11.8K 0.06% 251
2025
Q2
$810K Buy
7,305
+837
+13% +$89.1K 0.07% 220
2025
Q1
$725K Buy
6,468
+62
+1% +$6.4K 0.07% 217
2024
Q4
$592K Sell
6,406
-2,690
-30% -$242K 0.06% 257
2024
Q3
$763K Buy
9,096
+266
+3% +$20.3K 0.08% 217
2024
Q2
$661K Buy
8,830
+148
+2% +$9.88K 0.07% 232
2024
Q1
$636K Buy
8,682
+427
+5% +$32.8K 0.08% 219
2023
Q4
$669K Buy
8,255
+2,228
+37% +$173K 0.09% 197
2023
Q3
$452K Sell
6,027
-2,207
-27% -$170K 0.09% 203
2023
Q2
$635K Buy
8,234
+2,727
+50% +$217K 0.12% 160
2023
Q1
$457K Buy
5,507
+1,867
+51% +$155K 0.15% 148
2022
Q4
$312K Buy
+3,640
New +$288K 0.12% 184

Other funds holding GILD

Insigneo Advisory Services's GILD Position: Q2 2026 in Review

Insigneo Advisory Services increased its Gilead Sciences (GILD) stake by 7.5% in Q2 2026, buying an estimated $89.1K and bringing the position to 9,736 shares worth $1.23M. The position accounts for 0.05% of the portfolio, ranked #275.

Insigneo Advisory Services first reported a position in GILD in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.26M in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Insigneo Advisory Services held 9,736 shares of Gilead Sciences worth $1.23M as of Q2 2026.
  • Insigneo Advisory Services bought 676 Gilead Sciences shares in Q2 2026, an estimated $89.1K.
  • Gilead Sciences made up 0.05% of Insigneo Advisory Services's portfolio in Q2 2026, its #275 holding.
  • Insigneo Advisory Services first reported a position in Gilead Sciences in Q4 2022 and has held it in 15 quarters since.
  • Insigneo Advisory Services's Gilead Sciences position peaked at $1.26M in Q1 2026.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Insigneo Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.